SURVIVAL BENEFIT ASSOCIATED WITH FLUOROPYRIMIDINES, PLATINUM AGENTS, TAXANES, AND IRINOTECAN DURING ALL LINES OF TREATMENT IN PATIENTS WITH ADVANCED GASTRIC CANCER

被引：0
|
作者：
Shitara, K. [1 ]
Matsuo, K. [2 ]
Takahari, D.
Yokota, T. [1 ]
Ura, T.
Ito, S.
Sawaki, A.
Tajika, M.
Kawai, H.
Muro, K.
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
[2] Aichi Canc Ctr Res Inst, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：228 / 229
页数：2
相关论文
共 50 条
  • [11] Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis
    Lili Wu
    Ying Feng
    Zhijun Wu
    Hui Xu
    Cheng Zhang
    Jie Ning
    Rong Wang
    Jianqiong Chen
    Minmin Xie
    Yi Zhang
    Lijia Bu
    Jiqing Hao
    Tai Ma
    World Journal of Surgical Oncology, 19
  • [12] Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progressionfree survival in patients with advanced and/or metastatic colorectal cancer
    Wulaningsih, Wahyu
    Wardhana, Ardyan
    Watkins, Johnathan
    Yoshuantari, Naomi
    Repana, Dimitra
    Van Hemelrijck, Mieke
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [13] Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
    Aoki, Masahiko
    Shoji, Hirokazu
    Nagashima, Kengo
    Imazeki, Hiroshi
    Miyamoto, Takahiro
    Hirano, Hidekazu
    Honma, Yoshitaka
    Iwasa, Satoru
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Higuchi, Kazuhide
    Boku, Narikazu
    ESMO OPEN, 2019, 4 (03)
  • [14] The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer.
    Aoki, Masahiko
    Shoji, Hirokazu
    Imazeki, Hiroshi
    Miyamoto, Takahiro
    Hirano, Hidekazu
    Honma, Yoshitaka
    Iwasa, Satoru
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Boku, Narikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [15] Overall survival (OS) of patients with advanced gastric cancer (AGC) according to the availability of 5-FU, platinum, taxanes and irinotecan as first, second and third-line chemotherapy
    Kim, M. J.
    Yoo, K. H.
    Lee, S. J.
    Kim, S.
    Lee, J.
    Park, S. H.
    ANNALS OF ONCOLOGY, 2015, 26
  • [16] Chemotherapy and survival benefit in elderly patients with advanced gastric cancer.
    Sugimoto, Aya
    Nishida, Tsutomu
    Takahashi, Kei
    Mukai, Kaori
    Matsubara, Tokuhiro
    Hayashi, Shiro
    Yamamoto, Masashi
    Nakajima, Sachiko
    Fukui, Koji
    Inada, Masami
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [17] Impact of Treatment Sequencing on Survival for Patients with Advanced Gastric Cancer
    Li, Selena S.
    Mullen, John T.
    Costantino, Christina L.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : S265 - S266
  • [18] Irinotecan monotherapy as third line treatment for advanced gastric cancer patients refractory fluoropyrimidine, platinum and taxanes harboring UGT1A1*1/*1.*1/*6 or*1/*28
    Sugimoto, N.
    Yoshinami, T.
    Yagi, T.
    Hasegawa, A.
    Fujisawa, F.
    Imamura, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [19] Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
    Oba, Masaru
    Chin, Keisho
    Kawazoe, Yoshimasa
    Takagi, Koichi
    Ogura, Mariko
    Shinozaki, Eiji
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    ONCOLOGY LETTERS, 2011, 2 (02) : 247 - 251
  • [20] Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes
    Sánchez, R
    Esteban, E
    Palacio, I
    Fernández, Y
    Muñiz, I
    Vieitez, JM
    Fra, J
    Blay, P
    Villanueva, N
    Uña, E
    Mareque, B
    Estrada, E
    Buesa, JM
    Lacave, AJ
    INVESTIGATIONAL NEW DRUGS, 2003, 21 (04) : 459 - 463
12345